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With Type 2 Diabetes
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FOR THE PEDNID-LA RESEARCH GROUP
OBJECTIVE— To implement an educational program in 10 Latin American countries and to
evaluate its effect on the clinical, biochemical, and therapeutic aspects as well as the economic
cost of diabetes.
RESEARCH DESIGN AND METHODS— Educators from each participating country
were previously trained to implement the educational model. The patient population included
446 individuals with type 2 diabetes; all patients were ,65 years of age, did not require insulin
for metabolic control, did not have severe complications of diabetes or life-limiting illnesses, and
had not previously participated in diabetes education courses. Clinical and therapeutic data and
the cost of their pharmacological treatment were collected 6 months before participation in the
educational program (26 months), on entry into the program (time 0), and at 4, 8, and 12
months after initiation of the program.
RESULTS— All parameters measured had improved significantly (P , 0.001) by 1 year:
fasting blood glucose (mean 6 SD) 10.6 6 3.5 vs. 8.7 6 3.0 mmol/l; HbA1c 9.0 6 2.0 vs. 7.8 6
1.6%; body weight 84.6 6 14.7 vs. 81.2 6 15.2 kg; systolic blood pressure 149.6 6 33.6 vs.
142.9 6 18.8 mmHg; total cholesterol 6.1 6 1.1 vs. 5.4 6 1.0 mmol/l; and triglycerides 2.7 6
1.8 vs. 2.1 6 1.2 mmol/l. At 12 months, the decrease in pharmacotherapy required for control
of diabetes, hypertension, and hyperlipidemia represented a 62% decrease in the annual cost of
treatment ($107,939.99 vs. $41,106.30 [U.S.]). After deducting the additional cost of glucosuria
monitoring ($30,604), there was still a 34% annual savings.
CONCLUSIONS— The beneficial results of this educational model, implemented in 10
Latin American countries, reinforce the value of patient education as an essential part of diabetes
care. They also suggest that an educational approach promoting healthy lifestyle habits and
patient empowerment is an effective strategy with the potential to decrease the development of
complications related to diabetes as well as the socioeconomic costs of the disease.
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D iabetes presents a substantial socio-economic and quality-of-life bur-den (1), mainly as a consequence of
its chronic complications. Despite un-
equivocal data that chronic complications
can be prevented or delayed by improved
glycemic control and treatment of con-
comitant cardiovascular risk factors (2,3),
a large proportion of individuals with di-
abetes develop these complications.
One reason for the poor outcomes in
individuals with diabetes is the lack of
participation in the treatment of the dis-
ease. This participation is a key success
factor in the treatment of diabetes that de-
mands motivation, knowledge, and com-
pliance to a difficult and complex lifetime
regimen.
As early as 1875, Bouchardat (4) was
promoting patient education, daily urine
testing, and weight reduction as corner-
stones of therapy in type 2 diabetes; edu-
cation is widely accepted as integral to
diabetes therapy within the diabetes com-
munity (5–7). However, in many coun-
tries, only a minority of patients receive
diabetes education (8). Limited knowl-
edge of diabetes is frequent among indi-
viduals with diabetes (9). This deficiency
can be partly ascribed to the low priority
of patient education among practitioners,
payers, public health opinion leaders, and
decision-makers.
Educational programs are a signifi-
cant demand on health care providers, re-
quiring large blocks of time (generally
uncompensated), specific training, teach-
ing and communication skills, a support-
ive attitude, and a readiness to listen and
negotiate (10). Therefore, effective educa-
tion requires training in its delivery (11).
Furthermore, even if diabetes education
were to be accepted by health care pro-
viders and covered by health insurers,
many societies would not have sufficient
qualified diabetes educators to meet the
demand.
This lack of educational resources
will become critical in Latin America,
which the World Health Organization es-
timates to be among the regions with the
greatest increase in occurrence of diabetes
(12). Even now, 80% of the diabetes dis-
ability–adjusted life-years lost worldwide
occur in developing countries (13).
This problem was addressed by dia-
betologists from several Latin American
countries during a recent conference
sponsored by the Latin American Diabe-
tes Association (ALAD). They discussed
the feasibility of 1) finding a common and
flexible educational program suitable for
implementation in the countries of the re-
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gion, 2) enabling health care team mem-
bers to implement the program after a
brief training period, and 3) evaluating
the effect of the program on clinical,
biochemical, therapeutic, and economic
outcomes. ALAD decided to adapt a
structured group education model that
had been implemented successfully in
several European (14,15) and developing
countries (16,17). The results of this pro-
gram, the Programa de Educacio´n de Dia-
be´ticos No Insulinodependientes en
Ame´rica Latina (PEDNID-LA), are the
subject of this study.
RESEARCH DESIGN AND
METHODS
Structured educational model
The program was based on that of David-
son (18). It was designed and adapted to
local conditions by a multidisciplinary
group of health care professionals
(16,19). The course was presented to no
more than 10 ambulatory patients in a
group setting that allowed interaction be-
tween the educator and participants. The
primary goal of the course was to improve
health behavior.
The course included four weekly
teaching units (90–120 min each) and a
reinforcement session at 6 months. Fam-
ily members and spouses were encour-
aged to attend.
The first unit. The first teaching unit ac-
quainted patients with the interactive
group method, provided general con-
cepts about type 2 diabetes and self-
monitoring, and emphasized active
patient participation in treatment. Pa-
tients were introduced and asked to talk
about their diabetes. They were then in-
structed about the physiological changes
in serum glucose levels, the symptoms of
hypoglycemia and hyperglycemia, and
the renal threshold for glucose. As a
practicum, the patients were shown how
to perform and record glucosuria self-
monitoring. The urine glucose test was
chosen as the most practical means of
training patients with type 2 diabetes
about biochemical self-control; normo-
glycemia was not the goal of the program.
Additionally, the cost of self-monitoring
of blood glucose was unlikely to be borne
by the health care systems studied.
At the end of the first unit, the pa-
tients were asked to follow a low-calorie
diet (600 calories per day) on alternate
days until the next weekly session and to
discontinue use of oral hypoglycemic
agents (OHAs) to prevent hypoglycemia.
They were also asked to monitor glucos-
uria twice daily (2 h after the main meal)
and to record the findings in a logbook,
along with daily body weight. The goal
was to learn how food intake affects glu-
cose and glucosuria.
The second unit. During the second
teaching unit, the patients discussed the
evolution of their disease, the effect of
obesity on insulin sensitivity, and the ad-
vantages of weight reduction. Patients
were taught to assign foods to the catego-
ries of “recommended,” “neutral,” and “to
be avoided,” using the Plate Model, a sim-
ple alternative to the traditional exchange
method (20). The dinner plate shows the
portion of the plate that would be covered
by 100 calories of various foods. Benefits
include enhancement of the connection
between dietary theory and practice, pro-
motion of memory retention and under-
standing through visual messages, and
experience of a positive approach to nu-
trition counseling (20). Each patient de-
signed an individual meal plan (1,000 cal/
day) and was urged to follow it. The
educator reemphasized the importance of
glucosuria self-monitoring to observe the
influence of diet on metabolic control.
At the beginning of the third and
fourth teaching sessions, the patients had
an opportunity to discuss their experi-
ences with the meal plan, body weight,
and glucosuria self-monitoring initiated
during the first and second units.
The third unit. The main topics dis-
cussed during the third teaching unit
were foot care and regular physical ac-
tivity. The educator also performed foot
examinations.
The fourth unit. During the fourth
teaching unit, the basic rules for “sick
days” (intercurrent episodes of acute dis-
ease) were explained and examinations
and laboratory tests necessary for good
diabetes care were defined.
Educational materials. Educational ma-
terials used during the program included
the following: 1) a set of 25 colored flip
charts to illustrate the most important as-
pects of each unit; 2) teaching files for the
educator as a structured guideline on how
to perform each session; 3) a set of 50
photographs of different foodstuffs repre-
senting 100 cal each; 4) questionnaire
cards for distribution to participants as a
standardized procedure for verifying
knowledge acquired in previous sessions,
correcting misinterpretations, and rein-
forcing the main concepts; 5) individual
logbooks for recording all the self-
monitored data (glucosuria and body
weight); 6) patient booklets including the
main contents and other aspects of the
program; and 7) questionnaires for eval-
uation and documentation of the patients’
diabetes-related knowledge both before
and after the program. The same Spanish-
language materials were used in all coun-
tries except Brazil, where the materials
were translated into Portuguese. Addi-
tionally, some photographs of foodstuffs
characteristic of a particular country were
added to the materials used in that region.
Training of participating teachers
The program was implemented simulta-
neously in Argentina, Bolivia, Brazil,
Chile, Colombia, Costa Rica, Cuba, Mex-
ico, Paraguay, and Uruguay (see APPEN-
DIX). Before the program, all educators
participated in an intensive 10-person
2-day training seminar that included ba-
sic pedagogic principles, handling of
small interactive educational groups, us-
ing the education material, and achieving
the active participation of patients instead
of passive listening.
Patient selection and study design
The study was coordinated by a scientific
committee centered in La Plata, Argentina
(CENEXA), that was responsible for train-
ing the educators from the 10 participat-
ing countries in diagnostic testing (use of
the same reagents, kits, and laboratory
procedures), interventions, data regis-
tries, and analysis of results to ensure
standardization.
Inclusion criteria for participants
were type 2 diabetes, overweight or obe-
sity (BMI.27), and neither ketonuria nor
use of insulin. Exclusion criteria were
ages .65 years, advanced chronic com-
plications of diabetes (retinopathy, ne-
phropathy with creatinine .2 mg/dl, or
neuropathy), other severe life-limiting
illnesses, inability or unwillingness to
participate in the diabetes education pro-
gram and/or the diagnostic procedures of
the project, and participation in previous
structured diabetes education courses.
Individuals who fulfilled the inclusion
criteria and agreed to participate were in-
cluded in the study after providing in-
formed consent. This study conforms
with principles stated in the Declaration
of Helsinki.
Education of people with type 2 diabetes in Latin America
1002 DIABETES CARE, VOLUME 24, NUMBER 6, JUNE 2001
In each PEDNID-LA group, eligible
volunteers were selected randomly from
the patients who periodically came to
each clinic for control of diabetes. A total
of 658 patients were enrolled initially, but
records for the preceding year were in-
complete for 212 patients; therefore, the
final study group included 446 patients.
Statistical analysis showed no significant
differences between the clinical and bio-
chemical data recorded for the 446 pa-
tients who were studied and the 212
patients who were excluded (data not
shown).
After the completion of the program,
we evaluated clinical data, metabolic con-
trol and cardiovascular risk factors (obe-
sity/overweight, hypertension [systolic
and diastolic], and hyperlipidemia diag-
nosed according to the European Associ-
ation for the Study of Diabetes [EASD]
criteria) (21), drug intake (used to control
diabetes and other risk factors), and cost
of pharmacological treatment. For this
purpose, data were collected 6 months
before participation in the program (26
months), on entry into the program (time
0), and 4, 8, and 12 months after initia-
tion of the program (see RESULTS). After
completion of the program, data from
each patient were compared with data
from the same patient at time 0.
Clinical data included medical his-
tory, duration of diabetes, body weight,
BMI, drug intake, annual hospitalization
rate, major illness, cardiovascular symp-
toms, and smoking habits. Blood pressure
was measured at every visit, and 12-lead
resting electrocardiography was per-
formed annually in all participants. Data
were also recorded concerning blood
pressure and the daily intake of OHAs and
lipid-lowering agents.
Blood samples were collected at each
visit in the morning after 12 h of fasting
and after considering all other metabolic
and physical conditions of the patients as
stated in the PEDNID-LA protocol for
HbA1c (normal range 4.3–5.8%) (Tina
Quant HbA1c II; Roche Diagnostics,
Mannheim, Germany), glucose (glucose-
oxidase method; Roche Diagnostics),
total cholesterol, and triglycerides (enzy-
matic method; Roche Diagnostics). To
measure each of these biochemical pa-
rameters, the participating laboratories
strictly followed the instructions pro-
vided for each method by the manufac-
turer of the reagent used. In the particular
case of cholesterol analysis, the standard-
ization procedure followed the guidelines
of the National Education Program from
the U.S.
The data were recorded using a com-
mon data form and were sent to CENEXA
for compilation and analyses. To estimate
the changes in the cost of drugs taken by
the participants before and after the
courses, medications were classified as
OHAs, antihypertensive drugs, or choles-
terol-lowering drugs; glibenclamide, ena-
lapril, and simvastatin were selected as
representative of each of these classes, re-
spectively. The annual cost of medication
was estimated by multiplying the number
of patients using each drug the percentage
of patients taking each medication before
and after the program) by the average
daily intake and the average price of the
drugs on the Argentine market. Similar
reasoning was applied to estimate the an-
nual cost of the urine-glucose strips used
by all of the participants. In this case, we
assumed that none of the patients were
using strips at time 0 and all patients were
using them at 12 months.
Statistical analysis
The primary outcome was defined as a
difference between HbA1c levels mea-
sured at the beginning and the end of the
study. The power calculation was based
on a previous study with similar patient
characteristics (16). The formula used
(22) assumed the following: a-error 5
0.05; potency (1–b) 5 0.80; decreased to
be detected 5 0.5; standard deviation of
the expected change 5 1.5.
The data were analyzed at the
CENEXA facilities using the Database and
Statistical Program for Public Health Epi-
Info 6 (version 6.02; Centers for Disease
Control and Prevention and World
Health Organization, 1994) and the CSS/
Statistica software (Statsoft 1994). Differ-
ences between clinical and biochemical
parameters at different time periods were
obtained by repeated-measures analysis
of variance (Student-Neuman-Keuls post
hoc test), taking into account the varia-
tion in the number of cases recorded dur-
ing the study, whereas differences
between proportions in an unadjusted
univariate analysis were tested for statis-
tical significance by the x2 test.
RESULTS— The characteristics of the
446 patients who met all of the protocol
requirements and whose previous clinical
records were complete are shown in Table
1. The average duration of the disease was
8 years. Of the total participants, 92%
were either overweight or obese (n 5
410), 45% had systolic hypertension (n5
200), 44% had diastolic hypertension
(n 5 197), 62% had high serum choles-
Table 1—Main characteristics of the population sample
Characteristic Values Degree of control*
Sex
Female 64 —
Male 36 —
Age (years) 54.6 6 10.1 —
Duration of diabetes since diagnosis (years) 8.0 6 13 —
Drug intake‡
OHAs 76 —
Antihypertensive drugs 49 —
Cholesterol-lowering agents 10 —
BMI (kg/m2)† 31.5 6 5.6 24/25
Systolic blood pressure (mmHg)† 137 6 20.5 140
Diastolic blood pressure (mmHg)† 84.9 6 11.8 90
Fasting blood glucose (mmol/l) 10.2 6 3.3 ,6.1
HbA1c (%)† 8.9 6 2 ,6.5
Cholesterol (mmol/l)† 5.5 6 1.1 ,5.2
Triglycerides (mmol/l)† 2.1 6 1.4 ,1.7
Data are % and means 6 SD. *Figures correspond to “good” degree of control (21). †Total patient popula-
tion 5 446; 92% were obese (n 5 410), 45% had systolic hypertension (n 5 200), 44% had diastolic
hypertension (n 5 196), 62% had high serum cholesterol (n 5 277), 53% had increased triglyceride levels
(n 5 236), and 72% percent had HbA1c .6.5% (n 5 321). ‡The percentage is applied to the number of
people with the corresponding pathology, i.e., diabetes, hypertension, and high cholesterol levels, respec-
tively.
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terol (n 5 277), 53% had increased tri-
glyceride levels (n 5 237), and 72% had
HbA1c values .6.5% (n 5 323). The cri-
teria used to make these diagnoses were
those recommended by the EASD (21).
Patient follow-up varied by country.
Attendance at 12 months was 76%. Drop-
out was primarily financial; limited eco-
nomic resources hindered some patients’
regular participation. No significant dif-
ferences in clinical and biochemical char-
acteristics were observed between the
patients who dropped out of the program
and those who remained until the end of
the study (data not shown). The clinical
and metabolic parameters during the
1-year follow-up are summarized in Table
2. The fasting blood glucose levels for all
patients are reported, but in the case of
overweight/obesity, high blood pressure,
and serum lipids (cholesterol and triglyc-
erides), only abnormal values at baseline
are reported (21). Although data recorded
at baseline and –6 months were not sig-
nificantly different for all parameters
studied, significant differences were ob-
served between baseline values and val-
ues recorded at each time point during
the study, suggesting that the changes ob-
served resulted from the intervention.
Fasting blood glucose levels had de-
creased significantly (P , 0.001) at 1
month after the start of the study and re-
mained so throughout the study (Table
2). Similarly, HbA1c levels had decreased
by 1.2% at 1 year (P, 0.001) (Table 2) in
the 72% of patients in whom HbA1c was
measured (some centers were unable to
perform this analysis). Body weight had
decreased at 1 month after the start of the
study (21.4 kg) and remained stable (22
kg) from the fourth month after the start
of the study until the end of the study
(P , 0.05) (Table 2).
Systolic blood pressure decreased sig-
nificantly from EASD “borderline” target
levels (21) to near normal (153.8 6 15.9
to 142.9 6 18.8 mmHg, P, 0.005). The
diastolic blood pressure decreased to
EASD “good” control values (95.4 6 7.9
to 87.4 6 11.0 mmHg, P, 0.001) (Table
2). Cholesterol decreased significantly to
values near EASD “good” control (6.2 6
0.8 to 5.4 6 1.0 mmol/l, P, 0.001) (Ta-
ble 2) (21). Triglycerides also decreased
significantly, nearing EASD “fair” control
values (2.8 6 1.7 to 2.1 6 1.2 mmol/l,
P , 0.001) (Table 2) (21).
After 12 months, when we analyzed
only those patients who had a decrease in
the parameters measured, we found that
the fasting glucose level decreased in 53%
of the patients, HbA1c levels decreased in
60%, weight decreased in 65%, systolic
blood pressure decreased in 37%, systolic
blood pressure decreased in 41%, total
cholesterol decreased in 68%, and triglyc-
erides decreased in 56%. Wide variations
were observed in the decreases. When an-
alyzed by quartile, the first versus fourth
quartile changes were as follows: fasting
blood glucose –5.5 6 1.9 vs. –0.6 6 0.3
mmol/l; HbA1c –3.8 6 0.9 vs. 0.5 6
0.2%; body weight –6.9 6 3.5 vs. 0.8 6
0.3 kg; systolic blood pressure –29 6 8.6
vs. –8 6 2.6 mmHg; diastolic blood pres-
sure –94.5 6 15 vs. –83.1 6 8.2 mmHg;
total cholesterol –1.7 6 0.4 vs. –0.1 6
0.05 mmol/l, and triglycerides –2.2 6
1.3 vs. – 0.1 6 0.07 mmol/l. The largest
decreases (first quartile) obtained in all
parameters (except body weight) were
found in patients with higher initial val-
ues. Conversely, weight loss was related
only to the patients’ participating clinics.
There was a significant decrease in the
percentage of patients taking OHAs (76
vs. 48%, P , 0.001), antihypertensive
drugs (47 vs. 8%, P , 0.001), and cho-
lesterol-lowering agents (10 vs. 0%, P ,
0.02) at 12 months (Table 3). These ef-
fects were observed throughout the study
but were most pronounced immediately
after completion of the program. Overall,
the decrease in drug use represented a
marked reduction in the annual cost of
pharmacological treatment (a 62% de-
crease from $107,939.99 to $41,106.30
[U.S.]).
On the other hand, daily urine glu-
cose analysis by every patient represented
a new investment that added $30,604.00
(U.S.) per year (446 patients using one
strip daily for 365 days). If we subtract
that amount from the money saved by less
use of drugs ($66,833.69 – $30,604.00),
the net cost savings is $36,229.69 per
year, which is a 34% reduction in phar-
macotherapy costs.
CONCLUSIONS— Conflicting results
have been obtained regarding the effec-
tiveness of dietary advice on body weight
and metabolic control. Hadden et al. (23)
reported a cohort of patients who lost an
average of 9 kg during the first 6 months
and maintained the weight loss for 6
years; 87% of the patients were still being
treated with diet alone after 1 year and
71% were being treated with diet aloneT
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after 6 years. Conversely, two large mul-
ticenter studies, the University Group Di-
abetes Program Study (24) and the U.K.
Prospective Study (25), have found the
goal of weight loss to be more elusive. In
our study, the average 1-year decrease in
body weight was modest but consistent.
The relationship between weight loss and
the center where the patients were treated
support the contention of Heller et al.
(26): “It seems unlikely that the success of
some clinics and the abject failure of oth-
ers in achieving weight loss is related to
the diet prescription per se. It is more
likely to depend on how diet is taught and
the importance attached to it by those
who care for the patient.”
Our results confirm that lifestyle
modifications through patient education
result in a reduction in body weight and
better control of glucose, blood pressure,
and serum lipids (16,27,28). Maintaining
the mean decrease in HbA1c of 13% (from
9.0 to 7.8%) would represent a 20% life-
time decrease in the risk for microalbu-
minuria, a 56% decrease for neuropathy,
and a 64% decrease for progression of ret-
inopathy (29). The reduction in blood
pressure and serum lipids obtained
would also be expected to decrease car-
diovascular risk (29).
Our results demonstrate that educa-
tion of individuals with type 2 diabetes
can be both cost-effective and cost-
beneficial (7,8,16,17,26–28,30). Even af-
ter discounting the cost of self-monitoring
urine glucose levels, the decrease in drug
intake represents a mean savings of 34%
in pharmacotherapy. This decrease, along
with the corresponding reduction in the
lifetime risk for developing chronic com-
plications, could result in a diminution of
the socioeconomic burden and an im-
provement in quality of life for individu-
als with diabetes.
The dropout rate was significantly
lower than the 50% previously observed
in a similar population (1,16). We were
unable to identify a priori patient charac-
teristics predicting those who would or
would not successfully complete the fol-
low-up period. Identification of such
characteristics would be useful to identify
people who would benefit from a differ-
ent educational approach and is worthy of
further study.
Our study suggests that patient em-
powerment is an effective approach to de-
veloping educational interventions for
addressing the psychosocial aspects of liv-
ing with diabetes (31). Although no single
educational strategy has been demon-
strated to have a clear advantage (32),
group-oriented learning improves rela-
tionships between patients and health
care professionals, allows peer interac-
tion, and instills a sense of competition
(33). Moreover, our results further sup-
port the concept that an educational pro-
gram provided through small group
classes meets a variety of needs (e.g., cost-
effectiveness and convenience for pa-
tients, educators, and physicians) while
promoting adaptive changes in behavior
for improved food selection, increased
levels of physical activity, and improved
control of glycemia and risk factors asso-
ciated with type 2 diabetes (34).
The beneficial long-term clinical,
metabolic, and pharmacological effects of
the implementation of the current educa-
tional model have been reported in indi-
viduals with type 2 diabetes from
industrialized (8,14,15) and developing
countries (16,17) with gross differences
in socioeconomic and cultural condi-
tions. Because of the number of partici-
pating centers, the size of the sample, and
the methodology used for patient selec-
tion, the population recruited in each
center may not necessarily represent the
general population of each participating
country. However, the data do provide a
reasonable example of how social envi-
ronment and lifestyle habits vary in the
Latin American region. Despite this po-
tential limitation, the present study sup-
ports the flexibility of the model and the
possibility of extending its implementa-
tion to other countries with different
sociocultural settings.
Our results reinforce the need for and
the benefits of incorporating patient edu-
cation, either using this or other alterna-
tive models, as a regular and essential part
of diabetes care and as an effective means
of reducing chronic complications of dia-
betes. Furthermore, allocating resources
to such educational programs seems to be
a wise allocation of scarce funds in the
countries studied. The data presented sup-
port the idea that such an approach has
the potential to decrease the socioeconomic
costs of diabetes and to improve the qual-
ity of life of individuals with diabetes.
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APPENDIX
The PEDNID-LA administrative organiza-
tion was in charge of the Executive Com-
mittee and the General Coordinator, in
addition to the International Committee
for Technical Cooperation. The PEDNID-
LA Executive Committee includes Anto-
nio Chacra (Brazil), Gloria Lo´pez (Chile),
and Eric Mora Morales (Costa Rica). The
general coordinator is Juan Jose´ Gagliar-
Table 3—Annual changes in drug intake and cost
Drug
Period
% Decrease
0 12 months
Patients Tablets / year Cost / year Patients Tablets / year Cost / year
Oral hypoglycemic agent (Glibenclamide)* 339 247,470 $ 59,640.27 214 156,220 $37,649.02 —
Antihypertensive drug (Enalapril)† 98 71,540 $ 21,175.84 16 11,680 $ 3,457.28 —
Cholesterol-lowering drug (Simvastatin)‡ 28 20,440 $ 27,123.88 — — — —
Total 465 339,450 $107,939.99 230 167,900 $41,106.30 62%
Data are n and U.S. dollars. Cost estimations were performed considering the mean daily intake of each drug as stated below and the average cost of these drugs on
the Argentine market: *Glibenclamide, 5-mg tablets twice daily at $0.241 each tablet; †Enalapril, 5-mg tablets twice daily at $0.296 each tablet; ‡Simvastatin, 10-mg
tablets twice daily at $1.327 each tablet.
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dino of the CENEXA Center of Experi-
mental and Applied Endocrinology
(UNLP-CONICET, PAHO/WHO Collab-
orating Center) and the Bernardo A.
Houssay Center, La Plata, Argentina. In-
ternational Technical Cooperation in-
cludes Peter Kronsbein, Fachhochschule
Niederrhein Fachbereich Ernahrung/
Hauswirtschaft, Mo¨nchengladbach, Uni-
versitat Clinic, Du¨sseldorf, Germany.
Participating centers
Argentina: A. Alvarez, Hospital Italiano;
S. Lapertosa, M. Villagra, L. Candia, Hos-
pital de Corrientes; N. Ma´rquez, M. Tra-
versa, G. Sequeira, Hospital de Clı´nicas
Jose´ de San Martı´n; R. Mileo Vaglio, L.
Pereyra, A. Lucero, Centro de Diagno´stico
y Rehabilitacio´n Cardiovascular, San
Luis; E. Reynals, R. Aguilar, Facultad de
Ciencias Me´dicas, Universidad Nacional
de Cuyo; D. Assad, L. Co´ppola, M.I. Do-
menech, G. Etchegoyen, C. Gonzalez, E.
Lahera, Z. Zufriategui, Centro Bernardo
A. Houssay and CENEXA (UNLP-
CONICET).
Bolivia: D. Barraga´n Bauer, I. Cruz, I.
Gironda, Hospital San Gabriel.
Brazil: A. Chacra, San Pablo; M. Brito
Gomes, Rı´o de Janeiro; R. Chaves Fon-
seca, Salvador; A. Costa e Forti A, For-
taleza; J.L. Gross, Porto Alegre; A. Lerario,
San Pablo; M. Tambascia, Campinas.
Chile: E. Carrasco Pin˜a, G. Lo´pez
Stewart, G. Rojas Sepu´lveda, M. Bastı´as
Salgado, Facultad de Medicina, Unidad
de Diabetes.
Colombia: E. Arcos Palma.
Costa Rica: E. Mora Morales, F. Cartı´n
Ujueta, M. Fonseca Prado, G. Yung Li,
Hospital Dr RA Caldero´n Guardia.
Cuba: R. Garcı´a, R. Sua´rez, J. Calero,
M. Garcı´a, B. Me´ndez, La Habana.
Mexico: R. Quibrera Infante, San Luis
de Potosı´; J. Rı´os, Guadalajara; S. Zun˜iga,
Monterrey.
Paraguay: F. Can˜ete, G. Benı´tez, S.
Benitez, R. Morinigo, T. Paiva, Asuncio´n.
Uruguay: J.J. Fraschini, S. Garcı´a, A.
Pisano, B. Agazzi, M. Arguelle, M. Battle,
L. Brivio, R. Bueno, R. Deluca, R. Destef-
fanis, N. Freitas, S. Gil, M. Pereira, C. Ro-
driguez, M. Nun˜ez, C. Ruggiero, S.
Santana, Y. Testa, COMEF, Asoc. Esp. So-
corros Mutuos, CASMU, and Hospital
Maciel.
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